Company intelligence / Profile preview

Turning Point Brands

San Diego, California, United States

Ownership: Private
Employees: ~300
Development stage: Other

Overview

Turning Point's lead asset Augtyro (repotrectinib) is an FDA-approved next-generation tyrosine kinase inhibitor (TKI) for ROS1-positive metastatic non-small cell lung cancer and NTRK-positive solid tumors. It demonstrated significant efficacy in the TRIDENT-1 trial, including in patients previously treated with other TKIs and those with brain metastases.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Zai Lab

Beyond the preview

Go deeper on Turning Point Brands.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Turning Point Brands.

Explore the full profile